Motevasselian Mahtab, Omrani Mohammad Amin, Saleh Gargari Soraya, Younesi Sarang, Taheri Amin Mohammad Mahdi, Saadati Pourandokht, Jamali Soudabeh, Modarresi Mohammad-Hossein, Savad Shahram, Rahmani Majid, Amidi Saloomeh, Delshad Saeed, Navidpour Fariba, Chagheri Samira, Mohammadi Yalda, Khalilian Sheyda, Eslami Solat, Ghafouri-Fard Soudeh
Department of Obstetrics and Gynecology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Urology and Nephrology Research Center (UNRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mol Cytogenet. 2024 Dec 20;17(1):33. doi: 10.1186/s13039-024-00702-3.
The advent of non-invasive prenatal testing (NIPT) in the screening of fetal abnormalities has optimized prenatal care and decreased the rate of invasive diagnostic tests. In this retrospective descriptive study, we began with 1874 singleton pregnancies. After exclusion of some cases, the study cohort ended up with 1674 cases. We analyzed the performance of NIPT based on the results of first trimester screening (FTS) using serum screening combined with NT. The cases were also compared to diagnostic testing/pregnancy outcomes. Notably, in the subgroup with FTS risk < 1000, NIPT was reported to be normal in all cases with no false negative results. In the risk group of 1/300-1/1000, NIPT could detect all trisomy 21 cases with one false positive result. Moreover, in the risk group of 1/11 - 1/300, NIPT could detect all cases of trisomy 21, 13 and 18 with low false positive rate. However, the false positive rate for sex chromosomal abnormalities was high. Taken together, the current study confirms the applicability of NIPT as a tool for detection of fetal trisomies with high sensitivity and specificity. Yet, the high rate of false positive results for sex chromosome abnormalities should be considered in the interpretation of the results.
无创产前检测(NIPT)在胎儿异常筛查中的出现优化了产前护理,并降低了侵入性诊断检测的比率。在这项回顾性描述性研究中,我们从1874例单胎妊娠开始。排除一些病例后,研究队列最终有1674例。我们基于孕早期筛查(FTS)结果,采用血清筛查联合颈部透明带(NT)分析了NIPT的性能。这些病例还与诊断检测/妊娠结局进行了比较。值得注意的是,在FTS风险<1000的亚组中,所有病例的NIPT报告均为正常,无假阴性结果。在1/300 - 1/1000的风险组中,NIPT能检测出所有21三体病例,有1例假阳性结果。此外,在1/11 - 1/300的风险组中,NIPT能检测出所有21、13和18三体病例,假阳性率较低。然而,性染色体异常的假阳性率较高。综上所述,当前研究证实了NIPT作为一种高灵敏度和特异性的胎儿三体检测工具的适用性。然而,在结果解读中应考虑性染色体异常的高假阳性率。